No Data
No Data
Inhibikase Therapeutics Files to Sell 4.76M Shares of Common Stock for Holders
Inhibikase Therapeutics Shares Fall on Withdrawal of Patients in Parkinson's Trial
By Sabela Ojea Shares of Inhibikase Therapeutics on Tuesday dropped after the company said four people withdrew from its Parkinson's disease 201 trial without completing the 12-week timeline. The st
Express News | Inhibikase Therapeutics Completes Enrollment Of Its Phase 2 '201' Trial Of Risvodetinib In Untreated Parkinson's Disease
Express News | Inhibikase Therapeutics Inc: Expects to Report Trial Results in Q4 of 2024
Express News | Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8
Maxim Group analyst Jason McCarthy maintains $Inhibikase Therapeutics(IKT.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 29.
No Data